Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies

Richard Copin et al.

Summary: Monoclonal antibodies against SARS-CoV-2 are clinically validated therapeutic options against COVID-19. Studies show that non-competing antibody combinations in REGEN-COV provide protection against all current variants of concern and prevent the emergence of new variants.

CELL (2021)

Add to Collection

Article Multidisciplinary Sciences